ImmunityBio

IBRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.956 B

$8.45 -0.35%

Close of 21 Sept 2026

Revenue

$113.3M

#2463 by revenue

Earnings

-$351.5M

Loss-making

Shares outstanding

1,059,836,273

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#14Kymera TherapeuticsKYMR$9.78B
#15QiagenQGEN$9.23B
#16ImmunityBioIBRX$8.96B
#17RepligenRGEN$8.84B
#18VaxcytePCVX$8.77B

What if ImmunityBio were worth as much as…

Open the what-if tool →

Gold $30.3T

$28,564.84

Per share 3,380× higher

Bitcoin $1.72T

$1,622.71

Per share 192× higher

Nvidia $5.48T

$5,170.48

Per share 612× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for ImmunityBio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.